- Home
- INVA vs MESO Comparison
INVA vs MESO Comparison
Compare INVA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | MESO |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2000 | 2005 |
Fundamental Metrics
Financial Performance| Metric | INVA | MESO |
|---|---|---|
| Price | $20.98 | $14.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $35.00 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 571.5K | 262.8K |
| Earning Date | 11-13-2026 | 08-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 816.67 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $217,217,000.00 | N/A |
| Revenue This Year | $9.72 | $51.63 |
| Revenue Next Year | $8.58 | $63.39 |
| P/E Ratio | $16.92 | ★ N/A |
| Revenue Growth | ★ 62.63 | N/A |
| 52 Week Low | $17.87 | $11.89 |
| 52 Week High | $25.15 | $21.50 |
Technical Indicators
Market Signals| Indicator | INVA | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 57.35 |
| Support Level | $20.42 | $13.77 |
| Resistance Level | $21.69 | $16.06 |
| Average True Range (ATR) | 0.47 | 0.47 |
| MACD | 0.04 | 0.34 |
| Stochastic Oscillator | 70.40 | 82.19 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.